Cediranib
Ovarian Stromal Cancer
National Cancer Institute (NCI)Small moleculeN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Ovarian Stromal Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Carboplatin Beihua Kong | Phase 3 | BB |
Temsirolimus National Cancer Institute (NCI) | Phase 1 | CC |
Irinotecan National Cancer Institute (NCI) | Phase 1 | CC |
7-hydroxystaurosporine National Cancer Institute (NCI) | Phase 1 | CC |
EF-5 National Cancer Institute (NCI) | N/A | D |
LUTETIUM TEXAPHYRIN National Cancer Institute (NCI) | N/A | D |
Same molecule, other indications
Cediranib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →